Communiqués Thiogenesis Therapeutics, Corp.

Actions

TTI

CA88410L1022

Recherche biotechnologique et médicale

Marché Fermé - Toronto S.E. Autres places de cotation 16:02:03 03/07/2026			Varia. 5j.	Varia. 1 janv.
0,5700 ^CAD	+5,56%		+5,56%	-12,31%

17/06	Thiogenesis Therapeutics nomme Gilad Aharon à son conseil d'administration	MT
17/06	Thiogenesis Therapeutics, Corp. nomme Gilad Aharon à son conseil d'administration	CI

Communiqués

17/06	Thiogenesis Appoints Dr. Gilad Aharon to Its Board of Directors	NE
03/06	Thiogenesis Closes Oversubscribed Non-Brokered Private Placement for Gross Proceeds of C$9.07 Million	NE
01/06	Thiogenesis Upsizes Non-Brokered Private Placement of Common Shares	NE
11/05	Thiogenesis Announces Non-Brokered Private Placement	NE
16/04	Thiogenesis Therapeutics to Present at 2026 Bloom Burton & Co. Healthcare Investor Conference	NE
02/02	Thiogenesis Therapeutics Announces Investigator-Initiated Study in Nephropathic Cystinosis and Provides Program Update	NE
23/01	Thiogenesis Presents Phase 2 (EU) MELAS Data at Mitocon 2026	NE
13/01	Thiogenesis Therapeutics' MELAS Abstract Accepted for Late-Breaking News Presentation at Mitocon 2026	NE
05/01	Thiogenesis to Present Clinical Updates in MELAS and Leigh Syndrome Spectrum at UMDF Bench-to-Bedside Webinar	NE
09/12	Thiogenesis Therapeutics, Corp. to Present at the Life Sciences Virtual Investor Forum December 11th	AQ
24/11	Thiogenesis Therapeutics Expands on Plans for Phase 3 Pivotal Trial of TTI-0102 in Nephropathic Cystinosis	NE
04/11	Thiogenesis Reports Positive Interim Phase 2 Trial Results for MELAS and Announces Pipeline Advancements in Leigh Syndrome and Cystinosis	NE
03/10/25	Thiogenesis Announces Extension to Investor Relations Agreement	NE
11/09/25	Thiogenesis Reports on 2025 Annual General Meeting of Shareholders and Provides Corporate Update	NE
14/08/25	Thiogenesis Receives Final Acceptance from TSXV for Its Over-Subscribed Non-Brokered Private Placement of Common Shares	NE
01/08/25	Thiogenesis Raises over C$4.14 Million in Non-Brokered Private Placement of Common Shares	NE
29/07/25	Thiogenesis Upsizes Fully Subscribed Non-Brokered Private Placement of Common Shares	NE
17/07/25	Thiogenesis Announces Non-Brokered Private Placement of Common Shares	NE
25/06/25	Thiogenesis Receives Confirmatory Guidance on IMPD for Pediatric MASH Phase 2a Clinical Trial in Europe and Core Patent Granted in EU	NE
20/06/25	Thiogenesis Therapeutics to Present at UMDF's Mitochondrial Medicine 2025 Conference	NE
17/06/25	Thiogenesis Announces Second Site Begins Enrolling in Phase 2 MELAS Clinical Trial and Provides Update	NE
12/06/25	Thiogenesis Announces Grant of Stock Options	NE
11/06/25	Thiogenesis Announces FDA Clearance of its Investigational New Drug Application ("IND") for a Phase 2a Clinical Trial in Leigh Syndrome Spectrum	NE
14/05/25	Thiogenesis Initiates Phase 2 Clinical Trial in Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like Episodes ("MELAS")	NE
20/02/25	Thiogenesis Announces European Consulting and Investor Relations Agreement	NE